UCB S.A.

Specialty biologic prescriptions for chronic conditions carry strong refill characteristics—physicians and patients rarely discontinue a working therapy without clinical cause, providing year-on-year prescription continuity across immunology and neurology. Formal backlog or contractual visibility does not exist in the pharma model, and formulary changes can disrupt prescription flows.

UCB markets products across two therapeutic areas: immunology (Bimzelx, Cimzia, Rystiggo, Zilbrysq) and neurology (Briviact, Vimpat, Fintepla). Bimzelx represented approximately 30% of FY2025 net sales and Cimzia approximately 26%, together accounting for roughly 56% of net sales—a meaningful asset-level concentration offset by genuine cross-therapeutic spread.

UCB holds regulatory approvals and operates commercially across the US, EU, and Japan for key assets including Bimzelx, Rystiggo, and Briviact. Specialty biologic economics are disproportionately driven by US realized pricing, and Bimzelx's Time to Access Index declining to 43% in FY2025 reflects meaningful dependence on US formulary dynamics for revenue quality.

Adjusted EBITDA margin reached 34% of revenue in FY2025 as Bimzelx net sales scaled to €2.23 billion, levering the company's fixed commercial infrastructure across a substantially larger revenue base. Biologics manufacturing is capital-intensive, as evidenced by the committed $5 billion US greenfield manufacturing investment, constraining the asset-light economics seen in software-like models.

UCB's revenue derives from specialty biologics treating severe chronic conditions including moderate-to-severe psoriasis, psoriatic arthritis, generalized myasthenia gravis, and epilepsy, all of which are non-discretionary and mission-critical for patients. The absence of formal subscription contracts is offset by the structural demand continuity of treating long-duration chronic disease.